Regulation of VASP phosphorylation in cardiac myocytes: differential regulation by cyclic nucleotides and modulation of protein expression in diabetic and hypertrophic heart


Submitted 6 July 2009; accepted in final form 3 September 2009

**Address for reprint requests and other correspondence:** T. Michel, Brigham and Women’s Hospital, Cardiovascular Division, Thorn Bldg., Rm. 1210A, 75 Francis St., Boston, MA 02115 (e-mail: thomas_michel@harvard.edu).

http://www.ajpheart.org

First published September 4, 2009; doi:10.1152/ajpheart.00595.2009.

---

VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP) is the archetypal member of a family of actin-binding proteins termed the ENA/VASP protein family (34). This protein family includes the Drosophila protein Enabled (ENA), its mammalian homolog MENA, the ENA/VASP-like protein Evl, and VASP (13). MENA/VASP proteins are implicated in actin polymerization, and these proteins appear to modulate diverse cellular responses, including cell migration (26). VASP was initially isolated from human platelets (15, 16), and the protein has been extensively characterized as a substrate for cAMP- and cGMP-dependent protein kinases (40). Three phosphorylation sites (serine 157, serine 239, and threonine 278) have been identified in human VASP (38, 39). Ser157 is the preferred site for phosphorylation by the cAMP-dependent protein kinase (PKA), whereas Ser239 is the site preferentially phosphorylated by the cGMP-dependent protein kinase (PKG) (38, 39). Thr278 has recently been shown to be phosphorylated by the AMP-activated protein kinase (4). In different cell types, VASP phosphorylation pathways have been implicated in diverse cellular responses, ranging from endothelial cell permeability and angiogenesis (7, 8) to platelet aggregation and secretion (1, 2). Although VASP phosphorylation pathways have been extensively investigated in blood platelets and vascular smooth muscle cells, little is known about the modulation of VASP phosphorylation in the heart. Since abnormalities in cyclic nucleotide-modulated signaling pathways have been implicated in cardiomyopathy and heart failure (29), we decided, first, to explore the regulation of VASP phosphorylation in healthy mouse cardiac myocytes, and, second, to investigate whether VASP plays a role in the stressed heart.

In the normal mammalian heart, VASP expression appears to be enriched at the intercalated disks at the cell-cell boundaries between cardiac myocytes (12). However, mice with targeted deletion of VASP do not appear to show obvious developmental defects in cardiac structure or function (19), yet more detailed analyses of cardiac function in the VASP knockout mouse have not been reported. Transgenic mice overexpressing a dominant-negative VASP mutant in the heart develop a dilated cardiomyopathy and myocyte hypertrophy, associated with early postnatal lethality (10). Transgenic mice overexpressing the dominant-negative VASP mutant showed a displacement of both VASP and MENA from cardiac intercalated disks, suggesting that disruption of intercellular contacts in these transgenic mouse hearts contributes to their cardiac dysfunction (20, 21).

Little is known about VASP phosphorylation pathways in cardiac myocytes, despite the presence of diverse receptor-activated pathways that modulate the activation of adenylate and guanylate cyclases in these cells. In cardiac myocytes, cGMP is synthesized by two distinct guanylate cyclase isoforms: the soluble guanylate cyclase (sGC) isoform, which is...
activated by nitric oxide (NO), and the particulate guanylate cyclase, which is activated by binding atrial natriuretic peptide (ANP) (17, 25, 30). Both the endothelial (eNOS) and neuronal NO synthase (nNOS) isoforms are expressed in cardiac myocytes, and these cells are also responsive to extracellular NO from endothelial cells (coronary arteries) or from pharmacological sources of NO (11, 41). Of the multiple G protein-coupled receptors that lead to adenylate cyclase activation in cardiac myocytes, perhaps the best characterized is the β-adrenergic receptor pathway, which represents the archetypal pathway leading to cAMP accumulation in the heart. In these studies, we have explored the agonist-modulated pathways that regulate VASP phosphorylation in normal adult murine cardiac myocytes. We have also investigated VASP expression and phosphorylation in cardiac myocytes isolated from wild-type, diabetic (db/db), and VASPnull mice studied following aortic constriction in a cardiac hypertrophy model.

**EXPERIMENTAL PROCEDURES**

**Materials.** Polyclonal antibodies directed against phospho-VASP (Ser157 and Ser239), total VASP, MENA, phospho-eNOS (Ser1177), and Akt were from Cell Signaling Technologies (Beverly, MA). Total eNOS monoclonal antibody was from BD Transduction Laboratories (Lexington, KY). Collagenase type 2 was from Worthington Biochemical (Lakewood, NJ). Super Signal substrate for chemiluminescence detection and secondary antibodies conjugated with horseradish peroxidase were from Pierce. Tris-buffered saline and phosphate-buffered saline were from Boston Bioproducts (Ashland, MA). Laminin was from BD Bioscience (San Jose, CA). Minimum essential medium with Hank’s balanced salt solution and glutamine were from Gibco-BRL. Calf serum was from HyClone (Logan, UT). Laminin was from BD Bioscience (San Jose, CA). Minimum essential medium with Hank’s balanced salt solution and glutamine were from Gibco-BRL. Calf serum was from HyClone (Logan, UT). Isoflurane was from Abbott (North Chicago, IL). Heparin sodium was from APP (Los Angeles, CA). Pentobarbital sodium was from Ovation Pharmaceuticals (Deerfield, IL). Forskolin, 1 mM Na3VO4, 1 mM NaF, 2 μm leupeptin, 2 μm soybean trypsin inhibitor, and 2 μg/ml lima trypsin inhibitor). Cells were harvested by scraping and then rotated for 15 min at 4°C. For immunoblot analyses, 50 μg of cellular protein were resolved by SDS-PAGE. After separation by SDS-PAGE, proteins were electroblotted onto nitrocellulose membranes. After incubating the membranes in 5% nonfat dry milk in Tris-buffered saline with 0.1% (vol/vol) Tween 20 (TBST), membranes were incubated overnight in TBST containing 5% bovine serum albumin plus the specified primary antibody. After four washes (10 min each) with TBST containing 1% milk, the membranes were incubated for 1 h with a horseradish peroxidase-labeled goat anti-rabbit or anti-mouse immunoglobulin secondary antibody in TBST containing 0.1% milk. The membranes were washed four additional times in TBST containing 1% milk, then incubated with a chemiluminescent reagent, according to the manufacturer’s protocols (SuperSignal West Femto), and digitally imaged in a chemiluminescence imaging system (Alpha Innotech, San Leandro, CA). Quantitative analyses of the chemiluminescent signals were performed using an AlphaEase FC software (Alpha Innotech, San Leandro, CA). Where indicated in the experiments showing quantitative densitometry of Western blots, the ordinate is in arbitrary units.

**Statistical analysis.** All experiments were performed at least three times. Mean values for individual experiments were expressed as means ± SE. Statistical differences were assessed by ANOVA or t-test, as indicated. A P value of <0.05 was considered significant.

**RESULTS**

Isoproterenol-stimulated VASP phosphorylation in adult murine cardiac myocytes. Adult mouse cardiac myocytes were isolated, treated with the adrenergic agonist isoproterenol,
harvested, and analyzed in immunoblots, as described above. Figure 1A presents the results of immunoblot analyses exploring the time course of isoproterenol-induced phospho-VASP; the immunoblots were probed with selective antibodies, as shown. Note that phosphorylation of VASP on Ser157 leads to a shift in apparent molecular mass in SDS-PAGE from 46 to 50 kDa, as previously reported (17). Following the addition of isoproterenol (1 μM) to adult murine cardiac myocytes, phospho-VASP on Ser157 appears as a distinct band at 50 kDa, as seen in the immunoblots. The relative phosphorylation levels are shown in the densitometric analysis below each blot, with a significant increase observed at 5 min post-isoproterenol addition.

Fig. 1. Time-concentration responses for isoproterenol (ISO)-mediated vasodilator-stimulated phosphoprotein (VASP) phosphorylation and β1-adrenergic receptor blockade effect on ISO-induced VASP phosphorylation. Shown are the results of immunoblots analyzed in lysates prepared from adult murine cardiac myocytes treated with ISO (100 nM) for the indicated times (A) or concentrations (B; 5-min incubation with ISO), and treated with the β1-adrenergic antagonist atenolol (ATE) at the indicated concentrations and then treated with ISO (C; 100 nM for 5 min). Cell lysates were analyzed in immunoblots probed using antibodies directed against phospho-VASP (pVASP) Ser157, pVASP Ser239, total VASP, Akt, and GAPDH, as indicated. The experiment shown is representative of three independent experiments that yielded similar results. Below each immunoblot are the results of densitometric analyses from pooled data, showing the fold increase in VASP phosphorylation (in arbitrary units) in cardiac myocytes treated with ISO at the indicated times (A), ISO concentrations (B), or ATE concentrations (D) plotted relative to the signals present in unstimulated cells. Each data point represents the mean ± SE derived from three independent experiments. The results are significant at the *P < 0.05 level, **P < 0.01, and ***P < 0.001 for VASP phosphorylation vs. unstimulated cells (ANOVA).
phorylation of VASP at Ser157 and Ser239 rapidly and markedly increases, reaching a maximum response at 5 min, and slowly returning to baseline (Fig. 1A). This response is statistically significant. We next determined the isoproterenol dose response for VASP phosphorylation in these cells (Fig. 1B): mouse cardiac myocytes were treated for 5 min with varying concentrations of isoproterenol and analyzed in immunoblots probed with antibodies directed either against total VASP or with phosphospecific VASP antibodies, and with antibody directed against total Akt as loading control. Figure 1, top, shows immunoblot data from representative experiments; the bottom panels present the results of densitometric analyses of pooled data, which reveal that isoproterenol-stimulated VASP phosphorylation at Ser157 and Ser239 has an EC50 of ~10 nM.

Effects of the β-adrenergic antagonist atenolol on isoproterenol-promoted VASP phosphorylation. Figure 1C shows the results of immunoblot analyses performed in adult cardiac myocyte lysates prepared from cells incubated with the β-adrenergic antagonist atenolol at the indicated concentrations before treatment with isoproterenol. Immunoblots were probed with antibodies directed against phospho-VASP Ser157, phospho-VASP Ser239, total VASP, and GAPDH, as indicated. Figure 1D presents pooled data from three independent experiments analyzed by quantitative chemiluminescence of immunoblots. As can be seen in this figure, atenolol blocks isoproterenol-promoted VASP phosphorylations, with an IC50 of ~1 μM.

cAMP and isoproterenol-promoted VASP phosphorylation. We used pharmacological activators and inhibitor to explore the involvement of the cAMP/PKA pathway in VASP phosphorylation in cardiac myocytes (Fig. 2). In this figure, A, C, and E show the results of representative immunoblots, and B, D, and F show the results of densitometric analyses of pooled data for phosphorylation of VASP at Ser157 and Ser239. As shown in Fig. 2, A and B, the adenylate cyclase activator forskolin promotes VASP phosphorylation to a magnitude similar to that seen with isoproterenol, as does the cAMP analog, 8-(4-chlorophenylthio)adenosine-3’,5’-cyclic monophosphate acetoxymethyl ester (8-CPT-cAMP-AM) (Fig. 2, C and D). When cells are first treated with the PKA inhibitor...
compound H-89, subsequent isoproterenol-induced VASP phosphorylation is abrogated (Fig. 2, E and F). The nonselective phosphodiesterase (PDE) inhibitor 3-isobutyl-1-methylxanthine (IBMX), but not the PDE-5-selective inhibitor sildenafil, promoted a significant increase in VASP phosphorylation; in the presence of IBMX, addition of isoproterenol yields no additional VASP phosphorylation, (Fig. 2, G and H).

**VASP phosphorylation and NO signaling.** Our laboratory and others have previously reported that isoproterenol promotes activation of NOS in cardiac myocytes (3, 22), associated with changes in cyclic nucleotide signaling pathways. As shown in Fig. 3, A and B, we found that isoproterenol treatment of adult mouse cardiac myocytes promotes the phosphorylation of eNOS at Ser1177, a phosphorylation site associated with enzyme activation (28). The addition of isoproterenol to mouse cardiac myocytes promotes the rapid (Fig. 3A) and potent (Fig. 3B) phosphorylation of eNOS at Ser1177. The maximal response for isoproterenol-induced eNOS phosphorylation is seen at 15 min, with an EC50 of ~10 nM. We found that the NOS inhibitor Nω-nitro-l-arginine methyl ester (l-NAME) has no effect on isoproterenol-promoted VASP phosphorylation (Fig. 3, C and D). Similarly, the soluble guanylate inhibitor ODQ does not alter isoproterenol-promoted VASP phosphorylation in cardiac myocytes (Fig. 3, E and F). To further explore the role of NO pathways in isoproterenol-induced phospho-VASP, we analyzed responses in cardiac myocytes isolated from NOS gene-targeted mice. Figure 4, A and B, shows the results of immunoblots analyzed in cardiac myo-

![Fig. 3. Time concentration response for ISO-mediated eNOS phosphorylation at Ser1177 and the effects of NOS or guanylate cyclase inhibitor on ISO-induced VASP phosphorylation. This figure shows the results of time course (treated with 100 nM isoproterenol; A) and dose-response (treated with ISO for 5 min; B) experiments for ISO-stimulated eNOS phosphorylation in murine cardiac myocytes. C and E: results from cardiac myocytes incubated either with Nω-nitro-l-arginine methyl ester (l-NAME; 1 mM, 30 min) or with soluble guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinazolin-1-one (ODQ; 10 μM, 30 min), respectively, and then treated with ISO (100 nM, 5 min). Cell lysates were resolved by SDS-PAGE and probed using antibodies directed against phospho-eNOS (peNOS) Ser1177, total eNOS, pVASP Ser157, pVASP Ser239, total VASP, Akt, and GAPDH, as indicated. The experiment shown is representative of three independent experiments that yielded similar results. Below each immunoblot is shown the results of densitometric analyses from pooled data, plotting the fold increase of the degree of phosphorylation (in arbitrary units) of eNOS at the times (A) and concentrations (B) indicated, relative to the signals present in unstimulated cardiac myocytes. Each data point represents the mean ± SE derived from three independent experiments. *P < 0.05 and **P < 0.01 for eNOS phosphorylation vs. unstimulated cells (ANOVA). D and F: results of densitometric analyses from pooled data, plotting the fold increase in VASP phosphorylation relative to the signals present in the untreated cells. Each data point represents the mean ± SE derived from three independent experiments (ANOVA).
cytes treated with isoproterenol after isolation from eNOS−/− and wild-type mice and probed with antibodies directed against Ser157, Ser239 phospho-VASP, total VASP, eNOS, and Akt. Isoproterenol-promoted VASP phosphorylation is unaltered in cardiac myocytes isolated from the eNOS−/− mouse compared with the wild-type myocytes (Fig. 4, A and B). We then performed analogous experiments using cardiac myocytes isolated from nNOS knockout mice (Fig. 4, C and D). As found for the eNOS−/− mouse, the pattern of isoproterenol-promoted phospho-VASP did not differ between the nNOS−/− and wild-type cardiomyocytes.

**Guanlylate cyclase activation and VASP phosphorylation.** Although cardiac myocytes from both the eNOS−/− and nNOS−/− mice showed no substantive changes in VASP phosphorylation (Fig. 4), we still sought to explore whether an exogenous source of NO might activate sGC in these cells. Treatment of murine cardiac myocytes with the NO-donating drug sodium nitroprusside (SNP) showed a striking increase in phosphorylation of VASP at Ser239, with no effect on phosphorylation at Ser157 (Fig. 5, A and B). The SNP response was completely blocked by the sGC inhibitor ODQ (Fig. 5C). We also explored additional features of ANP-promoted VASP

---

**Fig. 4.** Isoproterenol-induced VASP phosphorylation in cardiac myocytes isolated from eNOS or neuronal NOS (nNOS) knockout mice. This figure shows results of immunoblots analyzed in lysates prepared from cardiac myocytes isolated from wild-type, endothelial (eNOSnull), or neuronal (nNOSnull) NOS knockout adult mice and treated with ISO (100 nM, 5 min). Cell lysates were resolved by SDS-PAGE and probed using antibodies directed against pVASP Ser157, pVASP Ser239, total VASP, eNOS, Akt, or GAPDH, as indicated. A and C: experiment shown are representative of three independent experiments each that yielded similar results. B and D: results of densitometric analyses from pooled data, plotting the fold increase in VASP phosphorylation relative to the signals present in the untreated cells. Each data point represents the mean ± SE derived from three independent experiments (ANOVA).
phosphorylation. As shown in Fig. 5, D and E, ANP treatment promotes the rapid phosphorylation of VASP Ser239, but has no effect on phosphorylation at Ser157. There was no effect of ODQ on ANP-promoted VASP phosphorylation (data not shown). We then performed an experiment in which cardiac myocytes were either treated with forskolin or cGMP-dependent protein kinase activator 8-bromo-cGMP. As shown in Fig. 5F, activation of cGMP-dependent kinases promotes phosphorylation of VASP at Ser239 only. Stimulation either of sGC (SNP) or of particulate guanylate cyclase (ANP) leads to VASP phosphorylation at Ser239. However, in contrast to the response elicited by isoproterenol, activation of cGMP pathways by NO or ANP does not promote VASP phosphorylation at Ser157.

VASP phosphorylation in cardiac myocytes isolated from db/db diabetic mice. Because of the postulated involvement of cyclic nucleotide signaling pathways in diabetic cardiomyopathy, we analyzed VASP expression and phosphorylation responses in cardiac myocytes isolated from db/db obese diabetic mice. As shown in Fig. 6, there is no change in the overall level of VASP expression in cardiac myocytes isolated from db/db mice compared with nonobese db/db littermates, normalized either to the abundance of actin or PKA in these samples. However, there is a marked increase in the basal levels of VASP phosphorylation at Ser157 and Ser239 sites. The striking increase in VASP phosphorylation in cardiac myocytes isolated from the db/db mouse was not significantly affected by the addition of isoproterenol to cells. In contrast, isoproterenol treatment of the nonobese db/+ littermates showed an increase in VASP phosphorylation at both Ser157 and Ser239, starting from a lower basal phosphorylation level. Importantly, treatment of cardiac myocytes isolated from the db/db mice with the PKA inhibitor H-89 completely reversed the increase in VASP phosphorylation seen in the diabetic animals (Fig. 6C),
without any accompanying change in expression of PKA (Fig. 6A). As shown in Fig. 6, D and E, neither insulin nor ANP promote any substantive change in VASP phosphorylation Ser157 in either db/+ or db/db cardiocytes. Both ANP and insulin promote a small but reproducible increase in phosphorylation of VASP residue Ser239 in cardiocytes isolated either from the db/db obese diabetic mice (E) or their wild-type littermates (db/+; D) and treated with ISO (100 nM for 5 min), insulin (INS; 1 μM for 15 min), or ANP (1 μM for 15 min). Each data point represents the mean ± SE derived from five independent experiments (ANOVA). VEH, vehicle.

VASP phosphorylation in cardiac myocytes isolated from mice subjected to AAC. Since cardiac myocyte hypertrophy involves changes in the cardiac actin cytoskeleton, and since the role of the actin-binding protein VASP in myocyte hypertrophy is unknown, we expanded our work to analyze VASP/MENA expression, along with VASP phosphorylation responses in cardiac myocytes isolated from wild-type mice (C57BL/6) subjected to AAC. As shown in Fig. 7, D, E, and F, following AAC, there is a significant increase in basal MENA and VASP expression, with a commensurate increase in VASP phosphorylation, as normalized to the abundance of either GAPDH or actin; sham-operated mice serve as a control. The marked increase in VASP phosphorylation in cardiac myocytes isolated from hypertrophic heart was further affected by the addition of isoproterenol to the cells (Fig. 8). The mice subjected to AAC developed significant cardiac hypertrophy, measured using echocardiography to determine the diastolic interventricular septum thickness (Fig. 7B). Echocardiography of mice subjected to AAC revealed no change in left ventricular systolic function (measured by the percentage of fractional shortening of the left ventricle) compared with sham-operated animals (Fig. 7C).

BP, heart rate, and the development of cardiac hypertrophy in VASP knockout mice. As shown in Fig. 9, A and B, VASPnull and VASP+/− mice had similar basal BP and resting heart rate. To explore the role that VASP plays in the stressed heart, we subjected mice lacking VASP to TAC, which subacutely
creases the workload on the heart. As shown in Fig. 9D, mice subjected to TAC, both VASPnull and VASP+/+ mice, developed cardiac hypertrophy 5 wk after surgery, without a significant decrement in cardiac systolic function (Fig. 9E). There was no substantive change in cardiac myocyte morphology between VASPnull and VASP+/+ mice (Fig. 9F).

**DISCUSSION**

These studies have used a combination of pharmacological, biochemical, and genetic approaches to explore VASP phosphorylation pathways in adult murine cardiac myocytes. We found that β-adrenergic receptor activation by isoproterenol rapidly leads to VASP phosphorylation at Ser157 and Ser239 (Fig. 1). Several lines of evidence in this study implicate cAMP-dependent signaling pathways as the principal mechanism modulating isoproterenol-induced phosphorylation of VASP at both sites in adult cardiac myocytes. Treatment of cardiac myocytes with either the cAMP analog 8-CPT-cAMP-AM or with the adenylate cyclase activator forskolin results in a pattern of VASP phosphorylation at Ser157 and Ser239 that is identical to the phosphorylation response seen with isoproterenol (Fig. 2, A–D). Inhibition of PKA by compound H-89 abrogates isoproterenol-induced phosphorylation of VASP at Ser157 and Ser239 (Fig. 2, E and F). The nonselective PDE inhibitor IBMX, but not the PDE-5-selective inhibitor sildenafil, promotes an increase in VASP phosphorylation (Fig. 2, G and H). In the presence of IBMX, addition of isoproterenol yields no additional VASP phosphorylation, suggesting that cyclic nucleotide PDEs, but not PDE-5, may play a role in modulating VASP phosphorylation. Taken together, these observations strongly implicate the β-adrenergic receptor/adenylate cyclase/cAMP/PKA pathway as the principal signaling system modulating the isoproterenol-induced phosphorylation of VASP at Ser157 and Ser239. We note that the immunoblots in this figure and throughout this paper reveal an apparent decrease in total VASP abundance following cAMP-AM or forskolin treatment, consistent with the known effects of these agonists on VASP phosphorylation. However, these changes do not significantly alter the ratio of phosphorylated to total VASP, as seen by the densitometric analyses in Fig. 2, E and F.
treatments with isoproterenol or other agonists that enhance VASP Ser157 phosphorylation. We interpret this decreased protein signal as reflecting a change in the apparent $M_r$ of VASP as a consequence of its phosphorylation (17): for reasons that remain poorly understood, protein phosphorylation is often accompanied by slower mobility on SDS-PAGE and sometimes (as appears to be the case for VASP) with a change in antigenicity. The transient decrease in the immunoblotted VASP signal following isoproterenol treatment appears to be a consequence of VASP Ser157 phosphorylation, leading to slower migration on SDS-PAGE, and also associated with a decreased affinity of the antibody for the phosphorylated protein.

A different pattern of VASP phosphorylation is seen following activation of cGMP-dependent pathways (Fig. 5). Murine cardiac myocytes are characterized by two distinct guanylate cyclase signaling pathways: the sGC, which is directly activated by NO, and the membrane-associated particulate guanylate cyclase, which is directly activated by ANP. NO in cardiac myocytes can be synthesized by either the endothelial isoform of NOS (eNOS) or by the nNOS isoform, both of which are expressed in these cells. Although the receptor-modulated pathways controlling nNOS activation in cardiac cells are less extensively characterized, we and others have clearly established that isoproterenol treatment of cardiac myocytes leads to the phosphorylation (Fig. 3) and activation of eNOS (3, 22). However, in the present studies, using both pharmacological and genetic approaches, we do not find evidence for the direct involvement of cardiac NOS pathways in modulating isoproterenol-induced VASP phosphorylation. We found that inhibition of NOS in cardiac myocytes by the NOS inhibitor L-NAME failed entirely to block VASP phosphorylation (Fig. 3, C and D). Basal as well as isoproterenol-promoted VASP phosphorylation was unchanged in cardiac myocytes isolated from eNOS$^{-/-}$ or nNOS$^{-/-}$ mice, arguing against a central role for endogenous NOS isoforms in control of VASP phosphorylation. Inhibition of sGC in these cells using the selective inhibitor ODQ similarly showed no significant effect on isoproterenol-modulated VASP phosphorylation (Fig. 3, E and F). These two lines of evidence point away from a central role for cardiac myocyte NOS-cGMP pathways in isoproterenol-mediated VASP phosphorylation and are consistent with our finding that $\beta$-adrenergic receptor-dependent VASP phosphorylation is entirely unchanged in cardiac myocytes isolated from nNOS$^{null}$ and eNOS$^{null}$ mice (Fig. 4). While it is formally possible that the eNOS and nNOS isoforms can compensate for one another when one or the other isoform is inactivated by gene targeting, this explanation seems less plausible, since neither NOS inhibition nor sGC inhibition affects the isoproterenol response (Fig. 3, C–F). Both eNOS

Fig. 8. ISO-induced VASP phosphorylation in cardiac myocytes isolated from hypertrophic hearts. This figure shows results of immunoblots analyzed in lysates prepared from cardiac myocytes isolated from mice subjected to AAC or sham-operated mice treated with ISO (100 nM for 5 min). A: cell lysates were resolved by SDS-PAGE and probed using antibodies directed against pVASP Ser157, pVASP Ser239, total VASP, actin, or PKA, as indicated. The experiment is representative of four independent experiments that yielded similar results. B: results of densitometric analyses from pooled data, plotting the fold increase in pVASP Ser157 or Ser239 relative to the signals present in untreated cells. Each data point represents the mean ± SE derived from four independent experiments (ANOVA).
and nNOS isoforms are constitutively expressed in cardiac myocytes, with some evidence that the endothelial and neuronal isoforms are localized to distinct subcellular compartment and have differential roles in cell signaling (11, 28, 41). eNOS is also robustly expressed in the vascular endothelial cells in the heart (11), and thus eNOS may play both an autocrine, as well as paracrine role in modulation of cardiac myocyte function. In contrast to the apparent lack of involvement of the endogenous NOS-sGC pathway in VASP phosphorylation, our experiments with ANP indicate that the particulate guanylate cyclase plays a role in VASP phosphorylation, albeit solely at Ser239, the site preferentially phosphorylated by the cGMP-dependent protein kinase (PKG). ANP does not promote VASP phosphorylation at Ser157. Phospho-VASP Ser239 is known to be the site preferentially phosphorylated by PKG (38), although both PKA and PKG can phosphorylate VASP at either site under some experimental conditions (6). Importantly, the SNP-induced increase in phospho-VASP Ser239 is completely blocked by the sGC inhibitor ODQ (Fig. 5C). This observation stands in marked contrast to the complete failure of ODQ to attenuate isoproterenol-induced VASP phosphorylation responses (Fig. 3, E and F). Taken together, these results suggest that exogenous but not endogenous sources of NO promote the sGC-dependent phosphorylation of VASP. At least part of the explanation of this apparent paradox may derive from the fact that eNOS and nNOS have highly restricted and distinct subcellular localizations in cardiac myocytes. eNOS is localized to caveolin-1-enriched cardiac myocyte T-tubules (11), whereas nNOS appears to be strictly segregated in the endoplasmic reticulum (41). By contrast, extracellular or pharma-
colocological sources of NO may be far more promiscuous in their cellular distribution (28). It seems quite plausible that eNOS, when localized in the vascular endothelium of cardiac blood vessels, or perhaps nNOS, located in cardiac nerve terminals, might play an important role in VASP modulation, even if these signaling enzymes, when expressed within purified cardiac myocytes, have little role in regulation of VASP. The spatial restriction of eNOS and nNOS to discrete subcellular locales may undermine these enzymes’ ability to activate sGC, whereas pharmacological NO donors, such as SNP, or paracrine sources of NO may not be limited by these spatial constraints and thus are able to robustly activate sGC in these cells. These results further suggest that modulation of VASP phosphorylation by NO represents a paracrine rather than an autocrine response, as is the case for many other NO-dependent signaling pathways. For example, VASP represents a target of endothelial cell-derived NO in the paracrine activation of sGC/PKG pathways that are located in vascular smooth muscle cells.

An important role for guanylate cyclases in VASP phosphorylation in cardiac myocytes is further established in experiments using the heart-derived peptide ANP (Fig. 5, D and E). ANP binds to and activates the particulate guanylate cyclase in target tissues, including cardiac myocytes, leading to striking increases in intracellular levels of cGMP in several cardiovascular tissues (25, 32). As we found for SNP, ANP promotes reversible phosphorylation of VASP at Ser239 in cardiac myocytes, without affecting Ser157 phosphorylation. The response to ANP is unaffected by the sGC inhibitor ODQ (data not shown), consistent with ANP’s known role in activation of the particulate guanylate cyclase, but not sGC (25). Additionally, activation of cGMP-dependent protein kinases by 8-bromo-cGMP or activation of adenylate cyclase by forskolin (Fig. 5F) further confirms the distinguished substrate specificity of cardiac VASP phosphorylation at Ser239 by cGMP and the indiscriminate specificity of cAMP as a substrate for both sites, Ser157 and Ser239.

These studies have established that the cardiac signaling pathways that modulate cyclic nucleotide responses also importantly influence VASP phosphorylation in cardiac myocytes. Some of these same signaling pathways are implicated in cardiac disease states. For example, ANP levels increase strikingly in heart failure, and the NO/cGMP pathway has been shown to attenuate hypertrophic responses in cardiac myocytes. In addition, the activation of adrenergic responses has been shown to accompany the development of heart failure. However, the role (if any) of VASP phosphorylations in cardiac pathophysiology is unknown. VASP has the ability to bind cytoskeletal proteins and regulate actin cytoskeleton dynamics (18, 26). Because diabetic cardiomyopathy involves pathological changes in cardiac actin cytoskeleton following left ventricular remodeling and loss of intracellular contacts (9, 31, 37), we decided to explore VASP expression and phosphorylation patterns in cardiac myocytes isolated from diabetic mice. Cardiomyocytes from diabetic heart had no change in total VASP expression (Fig. 6, A and B), nor in the abundance of PKA (Fig. 6A). However, we found a significant increase in basal VASP phosphorylation at both Ser157 and Ser239 sites (Fig. 6C). In cardiac myocytes isolated from db/db obese diabetic mice, there was no significant additional response to isoproterenol treatment on top of the augmented basal VASP phosphorylation already seen in these cells. However, inhibition of PKA with compound H-89 entirely abrogates the increased level of VASP phosphorylation at both Ser157 and Ser239, again demonstrating that the PKA pathway is a key determinant of phosphorylation responses at both sites.

Cardiovascular disease is the most common complication of diabetes (14). Murine models of diabetes, including the db/db obese diabetic mouse that was analyzed in the present studies, show evidence of cardiomyopathy associated with metabolic perturbations in cardiac myocytes, which occur independently of myocardial ischemia (reviewed in Ref. 1). We found no change in VASP expression in cardiac myocytes isolated from db/db mice, but basal VASP phosphorylation was increased (Fig. 6). VASP phosphorylation modulates actin dynamics (26), and it is plausible that the enhanced levels of phosphorylated VASP seen in myocytes from in both db/db diabetic (Fig. 6) and hypertrophic models (Figs. 7 and 8) may reflect the cytoskeletal remodeling that accompanies the transition to heart failure (27). There is no substantive alteration in the subtle insulin- or ANP-stimulated phosphorylation of VASP at Ser239 in cardiocytes isolated from db/db diabetic mice, nor is the robust insulin-dependent activation of kinase Akt altered in cardiac myocytes from diabetic mice. These findings suggest that insulin and ANP signaling to PKG is not significantly affected in the db/db model; the insulin-Akt axis is likewise unperturbed.

Because cardiomyopathy with systolic and diastolic dysfunction is evident in diabetic db/db mice (1, 36), we extended our work to analyze MENA/VASP expression and agonist-modulated VASP phosphorylation in cardiac myocytes isolated from hypertrophic hearts from mice subjected to AAC. The models of cardiac hypertrophy induced by AAC (Figs. 7 and 8) and TAC (Fig. 9) differ in their hemodynamic consequences and in the time course to development of heart failure. Cardiomyocytes from mice subjected to AAC show an increase in overall VASP abundance, with a corresponding increase in the absolute level of phosphorylated VASP. When the increase in phosphorylated VASP in cardiocytes is normalized to the increased level of total VASP expression seen following aortic constriction, the relative level of VASP phosphorylation is unchanged. It is notable that overall VASP phosphorylation is increased in cardiocytes isolated either from the db/db diabetic mouse or following AAC. Unfortunately, none of the commercially available VASP antibodies were found to yield a convincing signal in immunohistochemical studies of heart tissue (data not shown), despite the robust VASP expression documented in immunoblot analyses of isolated cardiocytes. Nonetheless, since VASP phosphorylation modulates actin assembly (28), it seems plausible that the absolute increase in the abundance of phosphorylated VASP may play a role in cytoskeletal remodeling in these mouse models of cardiac dysfunction.

The pathological cardiac phenotype that was previously documented in transgenic mice expressing a dominant-negative form of VASP pointed to a possible role for VASP in the modulation of cardiac cell shape and/or in ventricular remodeling (10). However, our initial findings in VASP

AJP-Heart Circ Physiol • VOL 297 • NOVEMBER 2009 • www.ajpheart.org

Downloaded from http://ajpheart.physiology.org/ by 10.220.32.246 on July 6, 2017

H1708  VASP MODULATION AND EXPRESSION IN CARDIAC MYOCYTES
response of heart to pressure overload or other stress conditions (5). To address the hypothesis of VASP as a modifier gene that could affect cardiac function under stress conditions, age-matched wild-type and VASP<sup>−/−</sup> mice underwent surgical aortic constriction, and cardiac function was evaluated in vivo by using two-dimensional echocardiography over the ensuing 5 wk. These studies did not identify a critical role for VASP during the increased hemodynamic load in the heart following aortic constriction (Fig. 9), in both cases showing hypertrophy without evident heart failure. Longer term studies of these and other models of cardiac hypertrophy and heart failure will be required to delineate the myocardial remodeling pathways regulated by VASP. It remains possible that VASP plays a key role in other pathophysiological processes in the heart. These studies have found that not only is VASP robustly expressed in cardiac myocytes (Fig. 7D) but also MENA, the second prominent member of the Ena/VASP-protein family. The colocalization of these two proteins has been found in many mouse tissues and suggests that these proteins may have similar overlapping functions; previous studies have suggested that VASP and MENA might be able to compensate for each other following knockout of one or the other gene (12, 19, 34). It is possible that the lack of a cardiac phenotype seen in the VASP<sup>−/−</sup> mouse may reflect functional compensation by MENA. These studies do not determine whether the increased expression of MENA and VASP, in association with augmented VASP phosphorylation in hypertrophic heart, modulates or reflects a marker for hypertrophy or cardiac dysfunction.

MENA. These studies do not determine whether the increased expression of these two proteins has been found in many mouse tissues and suggests that these proteins may have similar overlapping functions; previous studies have suggested that VASP and MENA might be able to compensate for each other following knockout of one or the other gene (12, 19, 34). It is possible that the lack of a cardiac phenotype seen in the VASP<sup>−/−</sup> mouse may reflect functional compensation by MENA. These studies do not determine whether the increased expression of MENA and VASP, in association with augmented VASP phosphorylation in hypertrophic heart, modulates or reflects a marker for hypertrophy or cardiac dysfunction in these mice, or whether VASP modulation might instead have a causal role. Further studies into the role and regulation of VASP and MENA in cardiac myocytes may provide new insights into the pathways controlling myocardial function in normal and diseased heart.

ACKNOWLEDGMENTS

We thank Drs. Ruqin Kou, Gordon Li, and Toru Sugiyama for helpful discussions and constructive critiques. We also thank Alex Loscalzo and Soeun Ngoy for excellent technical support.

GRANTS

The work was supported in part by National Institutes of Health Grants HL64657, HL48743, and GM36259 (to T. Michel), HL08533, HL093148, HL090884, and HL 071775 (to R. Liao), and by an American Diabetes Association/Takeda Cardiovascular Postdoctoral Fellowship Award (to J. L. Sartoretto).

REFERENCES